<DOC>
	<DOCNO>NCT01709994</DOCNO>
	<brief_summary>The objective study examine whether use low-dose aspirin ( 75-100 mg / day ) reduce risk cardiovascular disease patient chronic kidney disease ( stage 3 4 ) .</brief_summary>
	<brief_title>Primary Cardiovascular Risk Prevention With Aspirin Chronic Kidney Disease Patients</brief_title>
	<detailed_description>Hypothesis : The low-dose aspirin reduces cardiovascular risk patient chronic kidney disease without increase risk bleeding</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>sign inform consent male 4579 year females 5579 year . Stage 3 4 CKD ( estimate GFR MDRD abbreviate , 15 60 ml / min/1.73 m2 ) previous cardiovascular event : cardiac arrhythmia , cardiac arrest , angina acute myocardial infarction , stroke , carotid stenosis 50 % , peripheral vascular arteriopathy document hospitalization cause last three month prior inclusion study allergy acetylsalicylic acid coagulopathy cause thrombocytopenia &lt; 150,000 platelet liver disease cause Infection hepatitis B virus , hepatitis C HIV immunosuppressive treatment within 12 week inclusion study Major bleed event include gastrointestinal bleeding brain hemorrhage . hemoglobinopathy ( eg sickle cell disease thalassemia kind ) active malignancy ( except nonmelanoma skin cancer ) . May include study patient malignant neoplasia remain diseasefree least previous 5 year . uncontrolled inflammatory disease symptomatic ( eg rheumatoid arthritis , lupus , Chrom disease bowel inflammatory disease ) hemolysis treatment oral anticoagulation / antiplatelet therapy prior . poorly control hypertension ( &gt; 160/90 mm Hg ) pregnancy breast woman childbearing potential use effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>cardiovascular event</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>bleeding</keyword>
	<keyword>progression</keyword>
	<keyword>antiinflammatory effect</keyword>
</DOC>